[Congressional Record (Bound Edition), Volume 148 (2002), Part 10]
[House]
[Pages 13805-13808]
[From the U.S. Government Publishing Office, www.gpo.gov]




                              {time}  1945
               SENSE OF CONGRESS REGARDING OVARIAN CANCER

  Mr. BILIRAKIS. Mr. Speaker, I move to suspend the rules and agree to 
the concurrent resolution (H. Con. Res. 385) expressing the sense of 
the Congress that the Secretary of Health and Human Services should 
conduct or support research on certain tests to screen for ovarian 
cancer, and Federal health care programs and groups and individual 
health plans should cover the tests if demonstrated to be effective, 
and for other purposes.

[[Page 13806]]

  The Clerk read as follows:

                            H. Con. Res. 385

       Resolved by the House of Representatives (the Senate 
     concurring), That it is the sense of the Congress that--
       (1) the Secretary of Health and Human Services, acting 
     through the Director of the National Institutes of Health--
       (A) should conduct or support research on the effectiveness 
     of the medical screening technique of using proteomic 
     patterns in blood serum to identify ovarian cancer, including 
     the effectiveness of using the technique in combination with 
     other screening methods for ovarian cancer; and
       (B) should continue to conduct or support other promising 
     ovarian cancer research that may lead to breakthroughs in 
     screening techniques;
       (2) the Secretary should submit to the Congress a report on 
     the research described in paragraph (1)(A), including an 
     analysis of the effectiveness of the medical screening 
     technique for identifying ovarian cancer; and
       (3) if the research demonstrates that the medical screening 
     technique is effective for identifying ovarian cancer, 
     Federal health care programs and group and individual health 
     plans should cover the technique.

  The SPEAKER pro tempore (Mr. Grucci). Pursuant to the rule, the 
gentleman from Florida (Mr. Bilirakis) and the gentleman from Ohio (Mr. 
Brown) each will control 20 minutes.
  The Chair recognizes the gentleman from Florida (Mr. Bilirakis).


                             General Leave

  Mr. BILIRAKIS. Mr. Speaker, I ask unanimous consent that all Members 
may have 5 legislative days within which to revise and extend their 
remarks on H. Con. Res. 385 and to include extraneous material.
  The SPEAKER pro tempore. Is there objection to the request of the 
gentleman from Florida?
  There was no objection.
  Mr. BILIRAKIS. Mr. Speaker, I yield myself such time as I may 
consume.
  Mr. Speaker, I rise today in support of H. Con. Res. 385, which 
expresses the support of the Congress for research on tests to screen 
for ovarian cancer.
  Ovarian cancer ranks fifth in cancer deaths among women. 
Approximately 50 percent of the women in the United States diagnosed 
with ovarian cancer die as a result of the cancer within 5 years. The 
sooner ovarian cancer is diagnosed and treated, the better a woman's 
chance for recovery, since ovarian cancer is readily treatable when it 
is detectable before it has spread beyond the ovaries.
  If diagnosed and treated while the cancer is still limited to the 
ovary, the 5-year survival rate is 95 percent. However, only 25 percent 
of all ovarian cancers are found at this early stage, primarily because 
ovarian cancer is hard to detect early. Women with ovarian cancer often 
do not display symptoms until the disease is in an advanced stage. 
Without a reliable, easy-to-administer screening tool, we will continue 
to lose the battle to detect and treat this cancer in its early stages.
  This resolution expresses the sense of the Congress that the National 
Institutes of Health should conduct or support research on the 
effectiveness of screening technologies to detect ovarian cancer. The 
resolution also requests that the Secretary of Health and Human 
Services submit to Congress a report on this research, including an 
analysis on the effectiveness of these screening techniques.
  Finally, the resolution states that if the research demonstrates that 
the screening technique is effective for identifying ovarian cancer, 
Federal health programs and health plans should cover this new 
diagnostic test.
  It is important for women to get tested yearly for ovarian cancer. 
Effective screening techniques coupled with yearly exams will 
ultimately save lives. Mr. Speaker, I urge my colleagues to support 
this resolution.
  Mr. Speaker, I reserve the balance of my time.
  Mr. BROWN of Ohio. Mr. Speaker, I yield myself 2 minutes.
  Mr. Speaker, I want to thank the gentlewoman from Connecticut (Ms. 
DeLauro) and the gentleman from New York (Mr. Israel) for their efforts 
to address the need for continued research in ovarian health screening 
and subsequent coverage of proven testing methods by insurers.
  Ovarian cancer, the deadliest of the gynecologic cancers, is the 
fourth leading cause of cancer deaths among American women. It is 
estimated there will be over 23,000 new cases that get diagnosed, 
approximately 14,000 deaths from ovarian cancer just in this year alone 
in the U.S. There is no sound screening test to accurately detect 
ovarian cancer in its early stages like a pap smear for the detection 
of cervical cancer or a mammogram to detect breast cancer. While the 5-
year survival rate for women in the advanced stages of ovarian cancer 
is only 15 to 20 percent, for women in stage I of the disease, the 5-
year survival rate approaches 90 percent.
  This resolution encourages the development of an effective screening 
tool for ovarian cancer and promotes insurance coverage of effective 
screening tests. The Subcommittee on Health under the Committee on 
Energy and Commerce marked up this bill last week in committee. We 
passed it unanimously by voice vote. I urge my colleagues to support 
the resolution.
  Mr. BILIRAKIS. Mr. Speaker, I have no further request for time, and I 
yield back the balance of my time.
  Mr. BROWN of Ohio. Mr. Speaker, I yield 5 minutes to the gentleman 
from New York (Mr. Israel).
  Mr. ISRAEL. Mr. Speaker, I thank the gentleman for yielding me this 
time.
  Mr. Speaker, there are times when we can make a difference and 
sometimes it is the difference between life and death, and today is one 
of those days. We are considering a resolution that could begin a 
process that will save the lives of thousands of American women with 
ovarian cancer and women all over the world over the next several 
years.
  The resolution before us, which I introduced with the gentlewoman 
from Connecticut (Ms. DeLauro), distinguished colleague, calls on the 
National Institutes of Health to conduct a complete multi-institutional 
trial of a potentially huge breakthrough in the early detection of 
ovarian cancer.
  My colleagues have heard the statistics. About 75 percent of women 
diagnosed with ovarian cancer receive that diagnosis in the advanced 
stages of the disease when survival rates are only 20 percent. Ovarian 
cancer is the deadliest of gynecologic cancers. It is the fifth leading 
cause of cancer deaths among American women. One out of every 57 women 
are diagnosed with ovarian cancer. Last year nearly 14,000 women in 
America died from ovarian cancer.
  The statistics are alarming, but we can do something about them 
tonight. Thanks to Peter Levine and Dr. Ben Hitt, a reliable method of 
early detection may be near and that early detection takes the survival 
rate from 20 percent to 95 percent. This is something that saves lives. 
These are statistics that we can improve.
  The resolution calls for a full field test of the new ovarian cancer 
early detection process, and if that full trial of the simple blood 
test for ovarian cancer proves effective, I am going to fight to 
require that the blood test be given to all women as part of their 
annual gynecological exam and that Medicare/Medicaid and private 
insurance fully cover the procedure. It is a tough approach, but the 
time to act is now. In this case we can do something about the 
statistics. We can do something to save thousands of lives. We can make 
a difference.
  Our Nation has found the resolve and the resources to tackle the most 
difficult problems on earth, to produce the most advanced technology, 
to produce the most sophisticated weapons we need to protect our 
national security, and now we have an opportunity, using a simple stick 
upon a finger, to protect the health security of nearly 14,000 women. 
Now is the time for us to find the resolve and the resources to protect 
our people and our women from the ravages of ovarian cancer.
  Mr. Speaker, I want to thank the leadership of the Committee on 
Commerce for their bipartisan support. I want to thank the leadership 
of the entire Congress for their bipartisan support for this 
legislation that does put women ahead of politics. I urge my colleagues 
to support this important resolution.
  Mr. BROWN of Ohio. Mr. Speaker, I yield 3 minutes to the gentlewoman

[[Page 13807]]

from Connecticut (Ms. DeLauro), who has been one of the sponsors of 
this bill and has been a leader in all kinds of issues regarding 
women's health.
  Ms. DeLAURO. Mr. Speaker, I thank the gentleman from Ohio for 
yielding me this time.
  I stand here today in thanks to the gentleman from New York (Mr. 
Israel), and I want to express how proud I am to join with him on this 
resolution. I will explain why to my colleagues.
  So many people here know about my own set of health circumstances. 
Sixteen years ago, I was diagnosed with ovarian cancer. There is a 
moment when they tell you that you have cancer in which you go blank. 
You are not quite listening to anything that the doctor is telling you; 
you are only trying to figure out whether or not you are going to live 
or you are going to die.
  Ovarian cancer is a stealth disease. It does not know a political 
party; it does not know age; it does not know religious background; it 
just strikes. What is often the case is that women do not know they 
have ovarian cancer until the late stages, and that is often too late. 
By some, I say random luck, but I always view that someone was watching 
over me; I was diagnosed with ovarian cancer in the first stage so that 
it was treatable, though 16 years ago we did not have all of the new 
technology and this wonderful opportunity that we have to see expanded 
research by looking at blood samples and determining from the protein 
in those blood samples whether or not you have ovarian cancer. But it 
was random, and no one should live or die by randomness.
  We have an opportunity with this resolution to move forward in that 
early detection of ovarian cancer, and in these last 16 years, we have 
been unable to come forward with a screen, something like a mammogram 
which has been so helpful in determining the early stages of breast 
cancer so that we can save lives. That is what this resolution is 
about. It is about saving women's lives, because almost 14,000 women 
will die this year with ovarian cancer. If we had that screen, we could 
save 90 percent of them. They could go and be with their families, with 
their husbands, with their children, and have good lives.
  I know my colleagues will do the right thing on this resolution. Let 
us take advantage of modern technology, of biomedical research, and let 
us bring hope to the women of this country and their survival. I say 
``thank you'' from the bottom of my heart to Steve Israel, who asked me 
to join him on this resolution, and I say ``thank you'' to God every 
day for giving me my life back and my opportunity to serve in this 
institution, because this is the institution that can make things 
happen. We can save lives with this resolution.
  Ms. JACKSON-LEE of Texas. Mr. Speaker, I rise to support H. Con. Res. 
385 which expresses the sense of Congress that the Secretary of Health 
and Human Services should conduct or support research on certain tests 
to screen for ovarian cancer, and Federal health care programs and 
group and individual health plans should cover the tests if 
demonstrated to be effective.
  Experts estimate that more than 23,000 cases of ovarian cancer will 
be diagnosed this year with an estimated 13,900 women dying this year 
alone. While this is a sad reality, it is even more disturbing when we 
consider that ovarian cancer is a very treatable disease when it is 
detected early, but only 25 percent of ovarian cancer cases in the 
United States are diagnosed in the early stages. The vast majorities of 
cases are not diagnosed until the cancer has spread beyond the ovaries, 
often because symptoms are easily confused with other diseases and 
because reliable easily administered screening tools do not exist. 
Ovarian cancer is the deadliest of all gynecologic cancers, and is the 
fourth leading cause of cancer death among women in the United States.
  We all know about the remarkable scientific advances that are made 
each day. Today, people worried about certain illnesses may soon know 
for certain if they are at risk. Diseases that were once considered 
incurable are not preventable. Every day we are exploring new frontiers 
of the landscape of life and claiming new scientific victory. We are 
able to operate on infants still in the womb, extend the lives of heart 
patients with artificial hearts, and predict the development of disease 
through genetic coding. But there is a sad side of this story. There 
are diseases that do not receive the research attention that is 
necessary for advancement in treating and curing them. Ovarian cancer 
is one of those diseases.
  That is why we must actively support all promising new developments 
in research. Scientists from the Food and Drug Administration and the 
National Cancer Institute reported in the February edition of The 
Lancet that patterns of protein found in patients' blood serum may 
reflect the presence of ovarian cancer. In the study, scientists used 
serum proteins to detect ovarian cancer, even at its earliest stages. 
Using a test that can be completed in 30 minutes with blood from a 
finger prick researchers were able to differentiate between serum 
samples taken from patients with ovarian cancer and those from 
unaffected patients. This test was one step in a long journey. 
Additional, multi-institutional trials must be completed before the 
scientific community can agree that this is a reliable tool. That is 
why this resolution is so critical. We must push to make this test 
available to women. Saving at least one of the 13,900 who will die has 
to be our motivation.
  Currently, 50 percent of women diagnosed with ovarian cancer die from 
it within five years. When the disease is diagnosed in advanced stages, 
the chance of five-year survival is only 25 percent. Sadly, the 
situation for African American women is even more dismal. Among African 
American women, only 48 percent survive five years or more. Overcoming 
such persistent and perplexing health disparities and promoting health 
for all Americans must be a priority. That is why supporting research 
on medical screening techniques to identify ovarian cancer must rank as 
a priority for the Department of Health and Human Services.
  Early detection of this disease is the best way to save women's 
lives. The Department of Health and Human Service has done remarkable 
work researching deadly disease like cancer, Alzheimer's, diabetes and 
AIDS and giving hope to so many patients through this research. This 
resolution asks the Secretary of Health and Human Services to focus 
research on this unrecognized threat to the lives of women. 
Specifically, the Secretary should focus research on the effectiveness 
of the medical screening technique of using proteomic patterns in blood 
serum to identify ovarian cancer.
  Our scientists have tackled some of the most difficult problems known 
to man and have the potential to solve some of the most challenging 
health problems in the world. We must resolve to put all our resources 
behind their efforts particularly for diseases that affect populations 
that persistently experience health disparities.
  I support this legislation and thank the sponsor Mr. Israel and Ms. 
Rosa DeLauro who is a living testimony to how we can get results from 
good health care--because she is a survivor of ovarian cancer.
  Mr. DINGELL. Mr. Speaker, I commend the House for taking up this 
resolution raising the importance of ovarian cancer research and 
screening.
  Despite the severe consequences it poses to women's health, ovarian 
cancer is still under-recognized and under-researched. According to the 
American Cancer Society, more than 23,000 new cases of ovarian cancer 
will be diagnosed this year alone. An estimated 13,900 women will die 
of ovarian cancer in 2002, accounting for more deaths than any other 
cancer of the female reproductive system, and ranking as the fifth 
leading cause of cancer deaths in women.
  Ovarian cancer is highly treatable when discovered in its earliest, 
most treatable stages. Unfortunately, it is seldom discovered until it 
has spread. Only 78 percent of ovarian cancer patients survive one year 
and just over 50 percent survive five years after diagnosis.
  Currently, no simple standardized tests exist to detect ovarian 
cancer the way mammography can reliably check for breast cancer. This 
is why it is essential that Congress commit itself to research in the 
early detection of ovarian cancer.
  The good news is that since 1991, the ovarian cancer incidence rate 
has been on the decline. The best way to ensure the continuation of 
these waning numbers is to invest in improved testing and research. 
With multiple means of early detection on the horizon, it is essential 
that we address this important issue as soon as possible. I urge my 
colleagues to join me in support of this resolution.
  Mrs. MINK of Hawaii. Mr. Speaker, I rise today to ask all of my 
colleagues to vote for H. Con. Res. 385, which calls upon the Secretary 
of Health and Human Services to conduct or support research on certain 
tests to screen for ovarian cancer and to ensure that

[[Page 13808]]

Federal health care plans and group and individual health plans cover 
the tests if they are demonstrated to be effective. I am a proud co-
sponsor of this important legislation.
  As many of my colleague know, increasing research funding for ovarian 
cancer, especially for development of an early detection test, has been 
among my top legislative priorities for the past decade. My bill, H.R. 
326, the Ovarian Cancer Research and Information Amendments Act, has 
142 co-sponsors. I have introduced a similar bill in each Congress, 
beginning in 1991.
  I was thrilled to learn in February of this year of a blood test 
developed by Correlogic Systems Inc. of Bethesda, Maryland which has 
been studied by researchers at the National Cancer Institute and the 
Food and Drug Administration. In the study, scientists used a protein 
pattern they developed to classify 116 blood samples that were known to 
include 50 cancerous samples and 66 noncancerous samples. The test 
correctly identified the 50 cancerous samples and correctly identified 
95 percent of the control sample as noncancerous.
  It is urgent that large-scale testing of this technology be begun as 
soon as possible. As this test only requires a blood test, it will at 
last enable the widespread screening needed to identify this disease in 
its earliest and most curable stage. In particular, we should make the 
test available as soon as possible to those with increased risk factors 
for ovarian cancer.
  Approximately 23,000 women in the United States are expected to be 
diagnosed with ovarian cancer this year and some 14,000 women will die 
from the disease. Ovarian cancer is the most lethal cancer of the 
female reproductive system, primarily because it is so difficult to 
detect in its early stages. While survival rates are quite high if the 
disease is found before it spreads beyond the ovaries, the five-year 
survival rate drops to 28 percent for women who are diagnosed and 
treated in the later stages of the disease. Only 25 percent of ovarian 
cancer cases are caught in the earliest stage. This test could change 
these frightening statistics and lead to the declines in mortality 
we've seen since widespread use of early detection tests for cervical 
and breast cancer.
  I commend Representatives Israel and DeLauro for introducing this 
bill and urge all of my colleagues to support it.
  Mr. BROWN of Ohio. Mr. Speaker, I yield back the balance of my time.
  The SPEAKER pro tempore. The question is on the motion offered by the 
gentleman from Florida (Mr. Bilirakis) that the House suspend the rules 
and agree to the concurrent resolution, H. Con. Res. 385.
  The question was taken; and (two-thirds having voted in favor 
thereof) the rules were suspended and the concurrent resolution was 
agreed to.
  A motion to reconsider was laid on the table.

                          ____________________